Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

Ibizaman Aug. 19 at 11:35 AM

$SLS SLS. The Groundhog Day of shares, Until one day ........

0 · Reply

stwix Aug. 19 at 11:35 AM

$SLS The inadvertent revelation of dEeP value/Crafty Suntory is one of the most bullish happenings since the death of superBAT a month ago. The campaign fully backfired and screwed the background organization's almost year long tactic to part you and your shares before the last critical moment. Poor guy, I wouldn't be in his shoes.. All the analysis and prolific posts not just here but on other platforms are just the tip of the iceberg, group of experts were payed here. What we saw was not the product of a cheap 3rd world turdshop spitting BS 24/7. I wonder what the next trick is going to be. Sitting back, I am more relaxed about my decisions than ever.

0 · Reply

markbrogan Aug. 19 at 11:34 AM

$SLS I'm more bullish than ever and holding.

0 · Reply

Bgator Aug. 19 at 11:33 AM

$SLS Merck and Moderna CEOs on CNBC

1 · Reply

Picklez_ Aug. 19 at 11:33 AM

$SLS https://www.google.com/amp/s/www.cnbc.com/amp/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html

0 · Reply

BioCancerStop Aug. 19 at 11:32 AM

$SLS think how much better that would perform if they substituted GPS for Keytruda and the patient would not have all the nasty side effects of Keytruda also.

0 · Reply

Imr77 Aug. 19 at 11:32 AM

$SLS $JNJ better hurry up with the offer😉 or you will be left behind by $MRK

0 · Reply

ArbVinnie Aug. 19 at 11:32 AM

$SLS Moderna results in the melanoma trail should be a tailwind here

0 · Reply

MT_SLS Aug. 19 at 11:31 AM

$SLS GM all including Lefty And Y.

0 · Reply

Slstothamoon Aug. 19 at 11:30 AM

$SLS xbi/biotech indexes most likely going to be green today cause of MRNAs news Also a cancer vaccine showing such good results is amazing news for the world and sls Lets easily go past 13.50 today 🤞

1 · Reply

Sellas Life Sciences price target raised to $35 from $25 at Alliance Global

Aug 11, 2026, 4:05 PM EDT - 7 days ago

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 11, 2026, 7:00 AM EDT - 8 days ago

SELLAS Life Sciences Group Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

SELLAS Life Sciences Group Earnings release: Q2 2026

2026-07-17T16:06:56.000Z - 4 weeks ago

Sellas Life Sciences rises 11.0%

2026-07-17T14:05:57.000Z - 4 weeks ago

Sellas Life Sciences rises 10.2%

2026-07-06T11:05:22.000Z - 6 weeks ago

Sellas Life Sciences price target raised to $25 from $10 at Alliance Global

2026-07-01T14:05:22.000Z - 6 weeks ago

Sellas Life Sciences falls -11.0%

2026-06-30T14:05:32.000Z - 7 weeks ago

Sellas Life Sciences falls -8.9%

2026-06-29T14:05:39.000Z - 7 weeks ago

Sellas Life Sciences rises 16.8%

Jun 26, 2026, 12:30 PM EDT - 7 weeks ago

What's driving SLS stock higher today and what comes next?

Jun 16, 2026, 8:30 AM EDT - 2 months ago

SELLAS Life Sciences Group Transcript: AGM 2026

May 27, 2026, 9:00 AM EDT - 2 months ago

SELLAS Life Sciences Group Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026, 11:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 2:00 PM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 14, 2026, 8:00 AM EDT - 3 months ago

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 3 months ago

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Earnings release: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Mar 27, 2026, 8:05 AM EDT - 5 months ago

These 16 stocks are a short seller's dream — likely losers no matter what the market does

EVCM LCID NNE SERV

Mar 19, 2026, 4:05 PM EDT - 5 months ago

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 19, 2026, 4:00 PM EDT - 5 months ago

SELLAS Life Sciences Group Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 5 months ago

SELLAS Life Sciences Group Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 5 months ago

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

Mar 12, 2026, 8:35 AM EDT - 5 months ago

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Jan 14, 2026, 8:30 AM EST - 7 months ago

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 8 months ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 9 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

SELLAS Life Sciences Group Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

SELLAS Life Sciences Group Quarterly report: Q3 2025

Oct 29, 2025, 10:00 AM EDT - 10 months ago

SELLAS Life Sciences Group Transcript: R&D Day 2025

Oct 27, 2025, 8:30 AM EDT - 10 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Oct 10, 2025, 8:00 AM EDT - 11 months ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 10, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Jun 5, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q1 2025

Apr 28, 2025, 8:45 AM EDT - 1 year ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 1 year ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 8, 2025, 8:45 AM EDT - 1 year ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 20, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Annual report: Q4 2024

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Transcript: Study Update

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Press release: Study Update

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Earnings release: Q3 2024

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 2 years ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 2 years ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q1 2024

May 1, 2024, 8:35 AM EDT - 2 years ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Transcript: Study Update

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Press release: Study Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Ibizaman Aug. 19 at 11:35 AM

$SLS SLS. The Groundhog Day of shares, Until one day ........

0 · Reply

stwix Aug. 19 at 11:35 AM

0 · Reply

markbrogan Aug. 19 at 11:34 AM

$SLS I'm more bullish than ever and holding.

0 · Reply

Bgator Aug. 19 at 11:33 AM

$SLS Merck and Moderna CEOs on CNBC

1 · Reply

Picklez_ Aug. 19 at 11:33 AM

$SLS https://www.google.com/amp/s/www.cnbc.com/amp/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html

0 · Reply

BioCancerStop Aug. 19 at 11:32 AM

$SLS think how much better that would perform if they substituted GPS for Keytruda and the patient would not have all the nasty side effects of Keytruda also.

0 · Reply

Imr77 Aug. 19 at 11:32 AM

$SLS $JNJ better hurry up with the offer😉 or you will be left behind by $MRK

0 · Reply

ArbVinnie Aug. 19 at 11:32 AM

$SLS Moderna results in the melanoma trail should be a tailwind here

0 · Reply

MT_SLS Aug. 19 at 11:31 AM

$SLS GM all including Lefty And Y.

0 · Reply

Slstothamoon Aug. 19 at 11:30 AM

1 · Reply

Braggs91 Aug. 19 at 11:30 AM

$SLS bottom line is that we are now 29 months out from the last patients being enrolled in REGAL. If you think the BAT arm and a sudden “super BAT”’response — and not GPS training immune systems to attack the WT1 gene that mutated to cause leukemia — is the reason we haven’t reached 80 events yet, you should sell and leave. Bye bye! 👋

0 · Reply

summerof08 Aug. 19 at 11:29 AM

$MRNA wam bam, you like cancer vaccines, hop on the $SLS train for a bigger move upwards soon

0 · Reply

Timboslice88 Aug. 19 at 11:29 AM

$SLS so cancer vaccines work. That ends another short thesis.

0 · Reply

robcarroll Aug. 19 at 11:29 AM

$SLS big day for biotech coming with the “Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%” $MRNA $MRK https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html

0 · Reply

JRUKUKUK Aug. 19 at 11:27 AM

$SLS how many billions did Moderna just add on their mRNA cancer vaccine readout…. People still doubting where we will head on ours.

1 · Reply

BringDownThoseReps Aug. 19 at 11:27 AM

$SLS people will soon realize there is a pathway for cancer vaccines to work. Sellas on deck though with a different mechanism of action that is simpler and more scalable.

0 · Reply

Sellacious42 Aug. 19 at 11:27 AM

$SLS Did my part this morning, added 132 more shares to simple IRA. Soon, God willing, that 1750 spent will become 20,000. Calling on all real bulls, fake bulls to buy what they can before the train leaves the station. Calling on shorts to do what the chart, the trend, the science are telling you...cover!

1 · Reply

smwest3 Aug. 19 at 11:26 AM

$SLS

0 · Reply

Marcel20 Aug. 19 at 11:25 AM

$SLS look at Moderna🚀

0 · Reply

BostonDave Aug. 19 at 11:18 AM

$SLS I wasn't trying to mislead with this post. They used ML for SLS09. Sorry.

1 · Reply

summerof08 Aug. 19 at 11:17 AM

$SLS I’ve slightly put my life on hold for this read out. Sad, I know 😂

1 · Reply

EvolvedApe Aug. 19 at 11:14 AM

$SLS Hood morning. I’d like to quote a passage from Appalachians 4:20 “and the Lord looked down on Sellas Life Sciences and saw their efforts to smite neoplasms and he saw that it was good, and so he sayeth unto them “Go and make more and ye shall prosper..”. Amen.

1 · Reply

Market Cap	2.63B
Revenue (ttm)	0.00
Net Income (ttm)	-26.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,954,200
Avg Vol	8,279,344
Day's Range	N/A - N/A
Shares Out	201.95M
Stochastic %K	86%
Beta	2.48
Analysts	Strong Sell
Price Target	$32.50